Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Apatinib Consolidation in LS-SCLC
NCT06773156Phase 2Enrolling by invitation
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Nov 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in small cell lung cancer (SCLC), sponsored by The Second Affiliated Hospital of Nanchang University. Started Nov 2024; status: enrolling by invitation.
02
Drugs
adebrelimabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06773156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773156.